News

You may know that liver cancer is one of the most prevalent cancers, but do you know about its relationship with nonalcoholic steatohepatitis (NASH), which is rapidly increasing as a liver disease? The existence of NAFLD-related HCC, which we at SMC Laboratories, Inc. have been focusing on for more than 10 years, is now being…

READ MORE

We are pleased to announce that SMC Laboratories will be virtually attending the BIO One-on-One Partnering event next week from Monday, January 10th to Friday, January 14th.   If you are interested in attending BIO Partnering, please visit their website for more information on the event and how to register.

READ MORE

COVID-19 is a virus belonging to the beta-coronavirus class, similar to the virus that causes severe acute respiratory syndrome (SARS). It has been reported that fibrosis could begin to be observed several weeks after infection during the SARS epidemic. In subsequent follow-up studies, more than 20% of SARS survivors at one year later had pulmonary…

READ MORE

Marvel Biosciences, which is our client, has announced the results of pharmacology study using a STAM™ mouse model.   For detail information, see the Marvel's press release. Marvel Biosciences Lead Asset MB-204 Show 47% Reduction in Liver Fibrosis and Active Indications in Multiple Pre-Clinical Models of Nash | MARVEL Biotechnology  

READ MORE

We are pleased to announce the acceptance of our abstracts, “Molecular Pathogenesis of Non-Alcoholic Steatohepatitis (NASH) through the Dysregulation of Metabolic Organ Network in the NASH-HCC Model Mouse Treated with Streptozotocin-High Fat Diet” and “RNA-Seq Analysis of Liver from NASH-HCC Model Mouse Treated with Streptozotocin-High Fat Diet“—KDDW 2021, to be held from November 18 to 20,…

READ MORE

When discussing our unique NASH-HCC model STAM with clients, we are so often asked: What type of diabetes does the streptozotocin induce?   Since streptozotocin (an N-acetyl-β-D-glucosaminidase inhibitor; STZ) is cytotoxic to pancreatic beta cells, STZ-induced diabetes models are often considered as a model for Type 1 diabetes mellitus (T1D) which is in definition caused…

READ MORE

We are joining BioPharm America™ Digital, one of the most famous virtual biotech partnering and education events.   This digital event creates opportunities of exchange between executives from pharmaceutical/biotechnology companies of every size and stage, investors, and academic institutions. BioPharm America™ Digital gives opportunity for ventures within the life science realm to be explored through…

READ MORE

We will be attending the annual 24th BioJapan from Wednesday, October 13th, 2021 – Friday, October 15th, 2021 (10/13 – 15, 2021) at the Pacifico Yokohama Convention Center!   We are also going to give a formal convention presentation on the third day, Friday, October 15th, 2021 (10/15/2021). We would love to have the opportunity…

READ MORE

COVID-19 is now being recognized as a multi-organ disease that causes not only pneumonia, but also cause damage to other organs such as the liver, kidney and intestines. Recent reports have focused on lung fibrosis.       COVID-19 develops via infection with a virus belonging to the beta-coronavirus class, similar to the virus that…

READ MORE

ENYO Pharma (France) announced on 28 July, 2021, positive Vonafexor (EYP001) results for the LIVIFY phase 2a study in F2-F3 NASH patients over 12 weeks.   For detailed information, see the URL below. https://www.businesswire.com/news/home/20210728005557/en/ENYO-Pharma-Announces-Positive-Vonafexor-EYP001-Results-for-the-LIVIFY-Phase-2a-Study-in-F2-F3-NASH-Patients-over-12-weeks   Vonafexor is a synthetic non-steroidal, non-Bile Acid, highly selective FXR agonist.  This is used the STAM™ mouse model for non-clinical…

READ MORE